July 2026, Vol 16, No 4
After years of ongoing discussion at the federal level, we are finally seeing movement regarding pharmacy benefit manager (PBM) reform. In the March 2026 issue of Oncology Practice Management, we discussed some of the recent congressional, legislative, and investigative activities that surrounded movement by the Department of Labor (DOL) to publish proposed PBM regulation language for comment. Read More ›
Depression and anxiety affect up to 40% of patients with cancer and are consistently associated with lower quality of life, reduced treatment adherence, increased healthcare utilization, and poorer clinical outcomes. Read More ›
First impressions matter. In fact, studies show it takes just 7 seconds for your brain to form an opinion about someone. Read More ›
On March 13, 2026, the Maryland Insurance Administration (MIA) fined Cigna $80,000 and ordered the insurer to stop automatically downcoding evaluation and management (E/M) claims. Read More ›
By Taneal D. Carter, DHSc, MPA, MS; Ashley Orr, MPH; Mallory Stubblebine; Crystal S. Denlinger, MD; Alyssa Schatz, DrPH, MSW; Emma Wickland, MPH, CHES; Marcie Squirewell Wright, PhD; Robert A. Winn, MD
The NCCN, a nonprofit alliance of 33 cancer centers, is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention for all. Read More ›
On May 28, 2026, the FDA approved durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle invasive bladder cancer (NMIBC). Read More ›
On May 27, 2026, the FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare hematologic malignancy. Read More ›
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk (Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Read More ›